Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - October 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 6-9 October 2014. Topics discussed at the meeting:

• PRAC recommends strengthening the restrictions on the use of valproate in women and girls
• PRAC review does not confirm increase in heart problems with testosterone medicines
• PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig
• Five days left to respond to the consultation on public hearings

Read PRAC's monthly report from the meeting 6-9 October 2014